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Virus-speciﬁc cytotoxic T lymphocytes (CTLs) are major effectors in acquired immune
responses against viral infection. Virus-speciﬁc CTLs recognize speciﬁc viral peptides pre-
sented by major histocompatibility complex class-I (MHC-I) on the surface of virus-infected
target cells via their T cell receptor (TCR) and eliminate target cells by both direct and
indirect mechanisms. In human immunodeﬁciency virus (HIV) and simian immuno-
deﬁciency virus (SIV) infections, host immune responses fail to contain the virus and allow
persistent viral replication, leading to AIDS progression. CTL responses exert strong sup-
pressive pressure on HIV/SIV replication and cumulative studies have indicated association
of HLA/MHC-I genotypes with rapid or slow AIDS progression.
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INTRODUCTION
Innate and acquired immune responses play an important role in
the control of infectious pathogens. Pathogenic microbes are able
to escape from the host innate immune responses and replicate
in the hosts. After the acute growth phase,pathogen-speciﬁc neu-
tralizing antibody and cytotoxic T lymphocyte (CTL) responses
areinducedandpreventtheonsetof pathogenicmanifestationsin
most of acute infectious diseases. In HIV and simian immunode-
ﬁciency virus (SIV) infections, these acquired immune responses
are induced but fail to contain the virus and allow persistent viral
replication, leading to AIDS progression, while persistent SIVsm
infection of natural hosts, sooty mangabeys, does not result in
disease onset (Silvestri etal., 2003). Effective neutralizing anti-
body responses are not efﬁciently induced in the acute phase
(Burton etal., 2004). In contrast, virus-speciﬁc CTL responses
play a main role in the reduction of viral loads from the peak to
the set-point levels (Borrow etal.,1994; Koup etal.,1994; Matano
etal., 1998; Jin etal., 1999; Schmitz etal., 1999). Previous studies
suggest that, among various viral antigen-speciﬁc CTL responses,
those directed against the viral structural protein Gag contribute
to the control of viral replication (Edwards etal., 2002; Zuniga
etal.,2006; Borghans etal., 2007; Kiepiela etal., 2007).
In virus-infected cells, antigenic peptides that are processed
from viral proteins via the proteasome pathway and bound to
MHC-I (HLA class I) molecules are presented on the cell surface.
CTLsrecognizeantigenicpeptide(epitope)-MHC-Icomplexeson
thecellsurfacebytheirTCRsandeliminatethevirus-infectedcells
by inducing apoptosis or lysis. Because presentation of antigenic
peptidesisrestrictedbyMHC-Imolecules,CTLefﬁcacyisaffected
by MHC-I (HLA class I) genotypes.
ASSOCIATION OF HLA ALLELES WITH HIV PROGRESSION
HIV-infected individuals without anti-retroviral therapy (ART)
mostly develop AIDS in 5–10 years after HIV exposure
(Lui etal.,1988; Farewell etal.,1992). Humans have a single poly-
morphic HLA-A, HLA-B, and HLA-C locus per chromosome.
A number of studies on HIV-infected individuals reported the
association of HLA genotypes with disease progression (Tang
etal., 2002; Kiepiela etal., 2004; Wang etal., 2009; Leslie etal.,
2010). Indeed, association of HLA-B*57 (Migueles etal., 2000;
Altfeld etal., 2003; Miura etal., 2009) and HLA-B*27 (Goulder
etal., 1997; Feeney etal., 2004; Altfeld etal., 2006; Schnei-
dewind etal., 2007) with lower viral loads in the chronic phase
and slow disease progression has been indicated. HLA-B*57-
restricted Gag240−249 TW10 (TSTLQEQIGW) and HLA-B*27-
restrictedGag263−272 KK10(KRWIILGLNK)epitope-speciﬁcCTL
responsesexertstrongsuppressivepressureonHIVreplicationand
often select for viral genome mutations resulting in viral escape
from these CTL recognition with viral ﬁtness costs (Goulder etal.,
1997;Feeneyetal.,2004). SomeHIV-infectedindividualspossess-
ing those HLA alleles associating with slower disease progression
control viral replication for long periods, while the frequency of
such elite controllers is under 1% (Lambotte etal., 2005; Grabar
etal., 2009). In contrast, HLA genotypes such as HLA-B*35 asso-
ciating with rapid disease progression have also been reported
(Carrington etal., 1999; Gao etal., 2001). HLA-B*35 subtypes
are divided into HLA-B*35-Px and HLA-B*35-Py based on the
speciﬁcity of binding ability to epitope peptides in the P9 pocket.
The former group, HLA-B*35-Px alleles including HLA-B*3502,
B*3503, and B*3504 associate with rapid disease progression,
whereas the latter HLA-B*35-Py alleles including HLA-B*3501
andHLA-B*3508associatewithrelativelyslowerprogression(Gao
etal.,2001).SuchdifferencesindiseaseprogressionamongHLA-B
subtypes are also known in HLA-B*58 (Leslie etal., 2010).
ANIMAL AIDS MODELS
Robust non-human primate AIDS models showing high
pathogenic homology to human HIV infections are essential for
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AIDS research. While it is difﬁcult to analyze the early phase in
human HIV infection, animal models have considerable advan-
tages in immunological analysis in the acute phase. Furthermore,
comparisons among the hosts infected with the same virus strain
are possible in animal AIDS models, although highly diversi-
ﬁed HIVs are prevalent in humans. An important characteristic
of HIV infection is selective loss of memory CCR5+ CD4+
T lymphocytes in the acute phase leading to persistent virus
replication (Connor etal., 1997; Zhang etal., 1999; Brenchley
etal., 2004). HIV tropism for CCR5+ CD4+ memory cells is
considered as one central mechanism for persistent infection.
R5-tropic SIVmac251/SIVmac239 or SIVsmE660/SIVsmE543-
3 infection of rhesus macaques inducing the acute, selective
loss of memory CD4+ T lymphocytes is currently considered
the best AIDS model for analysis of AIDS pathogenesis and
evaluation of vaccine efﬁcacy (Veazey etal., 1998; Nishimura
etal., 2004; Bontrop and Watkins, 2005; Mattapallil etal., 2005;
Morgan etal., 2008). Recent studies indicated an associa-
tion of restriction factor TRIM5α genotypes with disease
progression in macaques infected with pathogenic SIVs such
as SIVsmE660/SIVsmE543-3 but not in SIVmac239 infection
(Kirmaieretal.,2010;Limetal.,2010;deGrootetal.,2011;Fenizia
etal., 2011; Letvin etal., 2011; Reynolds etal., 2011; Yeh etal.,
2011).MacaqueAIDSmodelsofchimericsimian-humanimmun-
odeﬁciency virus (SHIV) infection are also known. Infection with
X4-tropic SHIVs such as SHIV89.6P results in acute CD4+ Tc e l l
depletion,while R5-tropic SHIVs such as SHIV162P3 induce per-




GENETIC FEATURES OF MHC-I IN MACAQUES
HumanclassicalMHC-Iallelesarecomposedof asinglepolymor-
phic HLA-A,HLA-B,and HLA-C locus per chromosome. MHC-I
haplotypes in rhesus macaques, however, have variable num-
bers of Mamu-A and Mamu-B loci (Boyson etal., 1996; Adams
and Parham, 2001; Daza-Vamenta etal., 2004; Kulski etal., 2004;
Otting etal., 2005; Figure 1). A number of studies described SIV
infections in macaques sharing one or two MHC-I alleles, while
few studies have examined SIV infection in macaques sharing an
MHC-I haplotype.
PROTECTIVE MHC-I ALLELES IN INDIAN RHESUS
MACAQUES AGAINST SIV INFECTION
Simian immunodeﬁciency virus infections of Indian rhesus
macaques are widely used as an AIDS model. Mamu-A*01,
Mamu-B*08,andMamu-B*17 areknownasprotectivealleles and
macaques possessing these alleles tend to show slow disease pro-
gressionafterSIVmac251/SIVmac239challenge(Muhletal.,2002;
Mothe etal., 2003; Yant etal., 2006; Loffredo etal., 2007b). Four-
teen Mamu-A*01-restricted SIVmac239 CTL epitopes have been
reported (Allen etal., 2001; Mothe etal., 2002b). Mamu-A*01-
restricted Tat28−35 SL8 (STPESANL)-speciﬁc and Gag181−189
CM9 (CTPYDINQM)-speciﬁc CTL responses are induced dom-
inantly in SIVmac239 infection. Both epitope-speciﬁc CTLs
show strong suppressive capacity against SIVmac239 replication
FIGURE 1 | Comparison of genome structures of MHC-I sub-regions
in humans and rhesus macaques. Humans have a single polymorphic
HLA-A, HLA-B, and HLA-C locus per chromosome, while rhesus macaques
have variable numbers of Mamu-A and Mamu-B loci per chromosome.
in vitro (Loffredo etal., 2005), while the latter but not the for-
mer play a major role in suppression of viral replication in vivo
(O’Connoretal.,2002;Loffredoetal.,2007c).InSHIV89.6Pinfec-
tion, Mamu-A*01-positive macaques elicit CM9-speciﬁc CTL
responses and show slower disease progression than Mamu-
A*01-negative animals (Zhang etal., 2002). Eight Mamu-B*08-
restricted SIVmac239 CTL epitopes have been reported; previous
studies indicated that Vif123−131 RL9 (RRAIRGEQL), Vif172−179
RL8 (RRDNRRGL), and Nef137−146 RL10 (RRHRILDIYL)
epitope-speciﬁc CTL responses contribute to viral control
(Loffredo etal., 2007a; Loffredo etal., 2008; Valentine etal.,
2009; Mudd etal., 2012). SIVmac239 Vif66−73 HW8 (HLEVQ-
GYW), Nef165−173 IW9 (IRYPKTFGW), and Nef195−203 MW9
(MHPAQTSQW) have been reported as Mamu-B*17-restricted
CTLepitopes(Motheetal.,2002a). Inaddition,cRW9(RHLAFK-
CLW) in an alternate reading frame is known as a cryptic epitope
(Manessetal.,2007).ThecRW9-codingregion[nucleotides6889–
6915 in SIVmac239 (accession number M33262)] is located in the
same open reading frame that encodes exon 1 of the Rev protein
but is downstream of the splice donor site. So, it is not predicted
to be translated under normal biological circumstances. However,
SIVmac239-infected Mamu-B*17-positive macaques efﬁciently
induce cRW9-speciﬁc CTL responses.
ASSOCIATION OF MHC-I HAPLOTYPES WITH DISEASE
PROGRESSION AFTER SIVmac239 CHALLENGE IN
BURMESE RHESUS MACAQUES
WeaccumulatedgroupsofBurmeserhesusmacaquessharingindi-
vidual MHC-I haplotypes (Tanaka-Takahashi etal., 2007; Naruse
etal., 2010). SIVmac239 challenge of Burmese rhesus macaques
mostly results in persistent viremia (geometric means of setpoint
plasma viral loads: about 105 copies/ml) leading to AIDS (mean
survivalperiods:about2years; Nomuraetal.,2012).Furtheranal-
ysis revealed the association of MHC-I haplotypes with disease
progression after SIVmac239 challenge.
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Table 1 |Association of MHC-I haplotypes with disease progression in SIV infection (Nomura etal., 2012).
MHC-I Mean survival Geometric means of setpoint Peripheral CD4+ Predominant
haplotypes periods plasma viral loads (copies/ml) T cell decline CTL responses
90-120-Ia >40 months 104 Slow Gag/Nef
90-010-Ie 23 months 105 Intermediate Nef
90-120-Ib 24 months 105 Intermediate Nef
90-088-Ij 15 months 106 Rapid -
In our study (Nomura etal., 2012), the group of Burmese rhe-
sus macaques possessing MHC-I haplotype 90-010-Ie (dominant
MHC-I alleles: A1*066:01 and B*005:02) exhibited a typical pat-
tern of disease progression after SIVmac239 challenge (Table 1).
These animals showed predominant Nef-speciﬁc CTL responses,
approximately 105 copies/ml of setpoint plasma viral loads
(geometricmeans),and2yearsof meansurvivalperiods.Another
group of macaques possessing 90-120-Ib (dominant MHC-I alle-
les: A1*018:08 and B*036:03) showed similar setpoint viral loads
and survival periods. However, the group of Burmese rhe-
sus macaques possessing MHC-I haplotype 90-088-Ij (dominant
MHC-I alleles: A1*008:01 and B*007:02) showed higher setpoint
plasma viral loads (geometric means: about 106 copies/ml) and
shortersurvivalperiods(means:about15months;Table 1).These
animals mostly showed poor CTL responses.
In contrast, the group of Burmese rhesus macaques pos-
sessing MHC-I haplotype 90-120-Ia (dominant MHC-I alleles:
A1*043:01 and B*061:03), referred to as A+ animals, showed
lower setpoint plasma viral loads (geometric means: about 104
copies/ml) and slower disease progression (means of survival
periods: more than 40 months; Table 1). These animals predom-
inantly elicited Gag-speciﬁc and Nef-speciﬁc CTL responses after
SIVmac239 challenge. Mamu-A1*043:01-restricted Gag206−216
(IINEEAADWDL) and Mamu-A1*065:01-restricted Gag241−249
(SSVDEQIQW) were determined as dominant CTL epitopes.
SIVmac239-infected A+ animals selected viral escape mutations
from these epitope-speciﬁc CTL responses with viral ﬁtness costs
in the chronic phase (Kobayashi etal., 2005; Kawada etal., 2006).
These mutations are GagL216S, a mutation leading to a leucine
(L)-to-serine (S) substitution at the 216th amino acid in SIV-
mac239 Gag, and GagD244E, aspartic acid (D)-to-glutamic acid
(E) at the 244th,or GagI247L,isoleucine [I]-to-L at the 247th.A+
animalsimmunizedwithaprophylacticprime-boostvaccinecon-
sisting of a DNA prime followed by a boost with a recombinant
Sendai virus vector expressing SIVmac239 Gag controlled an
SIVmac239 challenge (Matano etal., 2004). However, vaccinated
A+ animalsfailedtocontrolachallengewithamutantSIVmac239
carrying GagL216S and GagD244E, indicating that Gag206−216-
speciﬁcandGag241−249-speciﬁcCTLresponsesareresponsiblefor
thecontrolof thewild-typeSIVmac239replication(Kawadaetal.,
2006, 2008). Interestingly, the Mamu-A1*065:01-restricted SIV-
mac239 Gag241−249 epitope is located in a region corresponding
to the HLA-B*57-restricted HIV Gag240−249 epitope TW10 and
TW10-speciﬁc CTL responses have also been indicated to exert
strong suppressive pressure on HIV replication. An SIVmac239
Gag241−249-speciﬁc CTL escape mutation, GagD244E, results in
loss of viral ﬁtness similarly with an HIV TW10-speciﬁc CTL
escape mutation. Both of the Mamu-A1*065:01-restricted SIV-
mac239 Gag241−249 epitope and the HLA-B*57-restricted HIV
TW10 epitope are considered to have the same anchor residues,
S at position 2 and tryptophan (W) at the carboxyl termi-
nus. Additionally, anchor residues of CTL epitopes presented
by Mamu-B*17/Mamu-B*08 were indicated to be similar to
those restricted by HLA-B*57/HLA-B*27 (Loffredo etal., 2009;
Wu etal.,2011).
CONCLUDING REMARKS
Human HLA genotypes largely affect disease progression in HIV
infection, reﬂecting that CTL responses play a central role in sup-
pressionof HIVreplication.AnimalAIDSmodelsarerequiredfor
understandingoftheinteractionbetweenhighlydiversiﬁedviruses
and the hosts with polymorphic MHC-I genotypes. SIV infection
of IndianrhesusmacaquesarewidelyusedasanAIDSmodel,and
association of certain MHC-I alleles with slower disease progres-
sionhasbeenindicated.WehaverecentlyreportedSIVinfectionof
Burmese rhesus macaques as a robust AIDS model and indicated
association of MHC-I haplotypes with disease progression. Accu-
mulation of those macaque groups sharing MHC-I haplotypes
could lead to constitution of a more sophisticated AIDS model
facilitating analysis of virus-host immune interaction.
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